Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Flu-Flop? Vaccine Shortage Becomes Presidential Campaign Issue

Executive Summary

The emergence of the flu vaccine shortage as a Presidential campaign issue suggests that longstanding recommendations on providing incentives to manufacturers may receive serious attention in 2005

You may also be interested in...



FDA Adverse Event Active Surveillance Extends Into Emergency Rooms

FDA has expanded its adverse drug event active surveillance program into 65 emergency rooms nationwide

FDA Adverse Event Active Surveillance Extends Into Emergency Rooms

FDA has expanded its adverse drug event active surveillance program into 65 emergency rooms nationwide

Vioxx, Drug Safety Issues Top Health Committee Agenda – If Gregg Stays

The Senate Health Committee plans to look into FDA's handling of Vioxx, antidepressant safety and flu vaccine, committee counsel Steve Irizarry said at the Healthcare Distribution Management Association annual meeting in Palm Desert, Calif. Nov. 4

Related Content

UsernamePublicRestriction

Register

PS044865

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel